Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia

Blood Cancer Journal

Volumn 6, Issue , 2016, Pages

  Patnaik, M M ^a   Tefferi, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADDITIONAL SEX COMBS LIKE 1 PROTEIN; BINDING PROTEIN; CBL PROTEIN; CD135 ANTIGEN; COHESIN; DNA METHYLTRANSFERASE 3A; HOMEODOMAIN PROTEIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; K RAS PROTEIN; ONCOPROTEIN; PLANT HOMEODOMAIN FINGER PROTEIN 6; PROTEIN P53; SERINE ARGININE RICH SPLICING FACTOR; SERINE ARGININE RICH SPLICING FACTOR 2; SET BINDING PROTEIN 1; SPLICING FACTOR 3B SUBUNIT 1; TET2 PROTEIN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX1; U2 SMALL NUCLEAR RNA AUXILIARY FACTOR; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; CHROMATIN; HISTONE; NONHISTONE PROTEIN; TRANSCRIPTION FACTOR;

CANCER PROGNOSIS; CHROMOSOME 7Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHRONIC MYELOMONOCYTIC LEUKEMIA; EPIGENETICS; GENE MUTATION; HUMAN; MOLECULAR PATHOLOGY; MONOSOMY 7; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; SPLICEOSOME; TRISOMY 21; TRISOMY 8; ANIMAL; CHEMISTRY; CHROMATIN; DNA DAMAGE; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDY; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; METABOLISM; MORTALITY; MUTATION; PROGNOSIS; PROTEIN MULTIMERIZATION;

ANIMALS; CELL CYCLE PROTEINS; CHROMATIN; CHROMOSOMAL PROTEINS, NON-HISTONE; CHROMOSOME ABERRATIONS; DNA DAMAGE; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, LEUKEMIC; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HISTONES; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MUTATION; PROGNOSIS; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION; SPLICEOSOMES; TRANSCRIPTION FACTORS;

EID: 84957561306     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2016.5     Document Type: Review

References (83)

1. Swederlow S, Camp E, Harris NL, Jaffe ES, Stefano PA, Stein H, et al. (eds). WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer: Lyon, France, 2008.
2. Patnaik MM, Parikh SA, Hanson CA, Tefferi A. Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol 2014; 165: 273-286.
3. Patnaik MM, Wassie EA, Lasho TL, Hanson CA, Ketterling R, Tefferi A. Blast transformation in chronic myelomonocytic leukemia: risk factors, genetic features, survival, and treatment outcome. Am J Hematol 2015; 90: 411-416.
4. Wassie EA, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. Am J Hematol 2014; 89: 1111-1115.
5. Such E, Cervera J, Costa D, Sole F, Vallespi T, Luno E et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011; 96: 375-383.
6. Patnaik MM, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia 2014; 28: 2206-2212.
7. Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013; 31: 2428-2436.
8. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840-849.
9. Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia 2013; 27: 1504-1510.
10. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616-3627, quiz 3699.
11. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
12. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 481-487.
13. Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006; 30: 965-970.
14. Curtis CE, Grand FH, Musto P, Clark A, Murphy J, Perla G et al. Two novel imatinibresponsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol 2007; 138: 77-81.
15. Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle 2007; 6: 550-566.
16. Patnaik MM, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol 2013; 88: 201-206.
17. Tang G, Zhang L, Fu B, Hu J, Lu X, Hu S et al. Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. Am J Hematol 2014; 89: 813-818.
18. Patnaik MM, Hanson CA, Hodnefield J, Knudson R, Van Dyke D, Tefferi A. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia 2010; 25: 266-270.
19. Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Holtan SG et al. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia 2010; 24: 1283-1289.
20. Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol 2012; 5: 12.
21. Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C et al. Clonal architecture of chronic myelomonocytic leukemias. Blood 2013; 121: 2186-2198.
22. McCullough KB, Patnaik MM. Chronic myelomonocytic leukemia: a genetic and clinical update. Curr Hematol Malig Rep 2015; 10: 292-302.
23. Itzykson R, Solary E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia 2013; 27: 1441-1450.
24. Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM et al. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood 2013; 121: 5068-5077.
25. Yamazaki J, Taby R, Vasanthakumar A, Macrae T, Ostler KR, Shen L et al. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics 2012; 7: 201-207.
26. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.
27. Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009; 23: 1343-1345.
28. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009; 23: 900-904.
29. Abdel-Wahab O, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood 2013; 121: 3563-3572.
30. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114: 144-147.
31. Ficz G, Branco MR, Seisenberger S, Santos F, Krueger F, Hore TA et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 2011; 473: 398-402.
32. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468: 839-843.
33. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010; 17: 13-27.
34. Quivoron C, Couronne L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011; 20: 25-38.
35. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011; 20: 11-24.
36. Ko M, Bandukwala HS, An J, Lamperti ED, Thompson EC, Hastie R et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci USA 2011; 108: 14566-14571.
37. Patnaik MM, Lasho TL, Vijayvargiya P, Finke CM, Hanson CA, Ketterling RP et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J 2016; 6: e385.
38. Patnaik MM, Wassie EA, Padron E, Onida F, Itzykson R, Lasho TL et al. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer J 2015; 5: e280.
39. Bejar R, Lord A, Stevenson K, Bar-Natan M, Perez-Ladaga A, Zaneveld J et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 2014; 124: 2705-2712.
40. Patnaik MM, Hanson CA, Hodnefield JM, Lasho TL, Finke CM, Knudson RA et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia 2012; 26: 101-105.
41. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553-567.
42. Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011; 25: 1153-1158.
43. Stegelmann F, Bullinger L, Schlenk RF, Paschka P, Griesshammer M, Blersch C et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia 2011; 25: 1217-1219.
44. Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011; 25: 1200-1202.
45. Balasubramani A, Larjo A, Bassein JA, Chang X, Hastie RB, Togher SM et al. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex. Nat Commun 2015; 6: 7307.
46. Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012; 22: 180-193.
47. Boultwood J, Perry J, Pellagatti A, Fernandez-Mercado M, Fernandez-Santamaria C, Calasanz MJ et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 2010; 24: 1062-1065.
48. Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145: 788-800.
49. Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adelaide J, Rey J et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009; 23: 2183-2186.
50. Carbuccia N, Trouplin V, Gelsi-Boyer V, Murati A, Rocquain J, Adelaide J et al. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia 2010; 24: 469-473.
51. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496-2506.
52. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861-1869.
53. Damaj G, Joris M, Chandesris O, Hanssens K, Soucie E, Canioni D et al. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One 2014; 9: e85362.
54. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079-1089.
55. Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 2013; 27: 82-91.
56. Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011; 118: 5593-5603.
57. Abdel-Wahab O, Kilpivaara O, Patel J, Busque L, Levine RL. The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia 2010; 24: 1656-1657.
58. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011; 29: 2499-2506.
59. Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011; 118: 3932-3941.
60. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-69.
61. Lasho TL, Jimma T, Finke CM, Patnaik M, Hanson CA, Ketterling RP et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood 2012; 120: 4168-4171.
62. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365: 1384-1395.
63. Aribi A, Borthakur G, Ravandi F, Shan J, Davisson J, Cortes J et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 2007; 109: 713-717.
64. Wu SJ, Kuo YY, Hou HA, Li LY, Tseng MH, Huang CF et al. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood 2012; 120: 3106-3111.
65. Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012; 120: 3080-3088.
66. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012; 119: 569-572.
67. Patnaik MM, Hanson CA, Sulai NH, Hodnefield JM, Knudson RA, Ketterling RP et al. Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. Blood 2012; 119: 5674-5677.
68. Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, Jadersten M et al. Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nat Commun 2015; 6: 5901.
69. Kon A, Shih LY, Minamino M, Sanada M, Shiraishi Y, Nagata Y et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 2013; 45: 1232-1237.
70. Wendt KS, Yoshida K, Itoh T, Bando M, Koch B, Schirghuber E et al. Cohesin mediates transcriptional insulation by CCCTC-binding factor. Nature 2008; 451: 796-801.
71. Parelho V, Hadjur S, Spivakov M, Leleu M, Sauer S, Gregson HC et al. Cohesins functionally associate with CTCF on mammalian chromosome arms. Cell 2008; 132: 422-433.
72. Van Vlierberghe P, Palomero T, Khiabanian H, Van der Meulen J, Castillo M, Van Roy N et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet 2010; 42: 338-342.
73. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2002; 2: 502-513.
74. Kuo MC, Liang DC, Huang CF, Shih YS, Wu JH, Lin TL et al. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia 2009; 23: 1426-1431.
75. Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010; 28: 3858-3865.
76. Ricci C, Fermo E, Corti S, Molteni M, Faricciotti A, Cortelezzi A et al. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res 2010; 16: 2246-2256.
77. Schnittger S, Bacher U, Alpermann T, Reiter A, Ulke M, Dicker F et al. Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases. Haematologica 2012; 97: 1890-1894.
78. Bersenev A, Wu C, Balcerek J, Tong W. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J Clin Invest 2008; 118: 2832-2844.
79. Koren-Michowitz M, Gery S, Tabayashi T, Lin D, Alvarez R, Nagler A et al. SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F. Br J Haematol 2013; 161: 811-820.
80. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918.
81. Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S et al. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol 2013; 88: 56-59.
82. Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 2013; 45: 942-946.
83. Laborde RR, Patnaik MM, Lasho TL, Finke CM, Hanson CA, Knudson RA et al. SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. Leukemia 2013; 27: 2100-2102.